Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The calcium receptor and calcimimetics.

M Wada1, N Nagano, E F Nemeth

  • 1Pharmaceutical Research Laboratory, Kirin Brewery Co. Ltd., Gunma.

Current Opinion in Nephrology and Hypertension
|September 24, 1999
PubMed
Summary

Calcimimetics, drugs that target calcium-sensing receptors, effectively lower parathyroid hormone secretion. Clinical trials show their potential for treating hyperparathyroidism and related bone conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.

Calcified tissue international·2015
Same author

Allosteric modulators of the extracellular calcium receptor.

Drug discovery today. Technologies·2013
Same author

Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis.

Kidney international·2007
Same author

Misconceptions about calcimimetics.

Annals of the New York Academy of Sciences·2006
Same author

The parathyroid polyhormone hypothesis revisited.

Kidney international. Supplement·2006
Same author

Summary--calcium receptors: potential targets for novel treatments for skeletal disease.

Journal of musculoskeletal & neuronal interactions·2005

Area of Science:

  • Endocrinology
  • Pharmacology
  • Nephrology

Background:

  • Parathyroid cells possess a calcium-sensing receptor (CaR) crucial for regulating plasma Ca2+.
  • Abnormalities in parathyroid hormone (PTH) secretion are linked to various diseases.

Purpose of the Study:

  • To evaluate calcimimetics as potential therapeutic agents for hyperparathyroidism.
  • To explore the role of CaR modulation in managing PTH secretion.

Main Methods:

  • Utilized calcimimetics, specifically NPS R-568, as agonists/modulators of the Ca2+ receptor.
  • Conducted clinical trials in patients with primary and secondary hyperparathyroidism.

Main Results:

  • Calcimimetics demonstrated the ability to suppress parathyroid hormone secretion.

Related Experiment Videos

  • NPS R-568 showed promise in clinical trials for hyperparathyroidism.

    • Conclusions:

    • Calcimimetics represent a novel therapeutic strategy for hyperparathyroidism.
    • These compounds may also be beneficial in treating related bone diseases like osteitis fibrosa.